Caveolin-1 has a complex role in
prostate cancer and has been suggested to be a potential
biomarker and therapeutic target. As mature
caveolin-1 resides in caveolae, invaginated
lipid raft domains at the plasma membrane, caveolae have been suggested as a
tumor-promoting signaling platform in
prostate cancer. However, caveola formation requires both
caveolin-1 and cavin-1 (also known as PTRF; polymerase I and transcript release factor). Here, we examined the expression of cavin-1 in prostate epithelia and stroma using tissue microarray including normal, non-malignant and malignant prostate tissues. We found that
caveolin-1 was induced without the presence of cavin-1 in advanced prostate
carcinoma, an expression pattern mirrored in the PC-3 cell line. In contrast, normal prostate epithelia expressed neither
caveolin-1 nor cavin-1, while prostate stroma highly expressed both
caveolin-1 and cavin-1. Utilizing PC-3 cells as a suitable model for caveolin-1-positive advanced
prostate cancer, we found that cavin-1 expression in PC-3 cells inhibits anchorage-independent growth, and reduces in vivo
tumor growth and
metastasis in an orthotopic
prostate cancer xenograft mouse model. The expression of α-smooth muscle actin in stroma along with
interleukin-6 (IL-6) in
cancer cells was also decreased in
tumors of mice bearing PC-3-cavin-1
tumor cells. To determine whether cavin-1 acts by neutralizing
caveolin-1, we expressed cavin-1 in caveolin-1-negative
prostate cancer LNCaP and 22Rv1 cells.
Caveolin-1 but not cavin-1 expression increased anchorage-independent growth in LNCaP and 22Rv1 cells. Cavin-1 co-expression reversed
caveolin-1 effects in caveolin-1-positive LNCaP cells. Taken together, these results suggest that
caveolin-1 in advanced
prostate cancer is present outside of caveolae, because of the lack of cavin-1 expression. Cavin-1 expression attenuates the effects of non-caveolar
caveolin-1 microdomains partly via reduced
IL-6 microenvironmental function. With circulating
caveolin-1 as a potential
biomarker for advanced
prostate cancer, identification of the molecular pathways affected by cavin-1 could provide novel therapeutic targets.